cancers

IMPACT FACTOR 4.5

Indexed in: PubMed

CITESCORE 8.0

an Open Access Journal by MDPI

# Current Updates and Future Directions in Neuroendocrine Neoplams (NENs): Understanding Biology, Diagnosis, Management and Research Efforts in NENs

Guest Editors:

**Dr. Jaydira del Rivero**
National Cancer Institute (NCI), Bethesda, MD, USA

**Dr. Aman Chauhan**
Sylvester Comprehensive Cancer Center, University of Miami, Coral Gables, FL, USA

Deadline for manuscript submissions:
**20 March 2025**

## Message from the Guest Editors

Neuroendocrine neoplasms (NENs) are categorized as neuroendocrine tumors (NETs) or neuroendocrine carcinomas (NECs). These are rare malignancies which occur, for example, in the gastrointestinal tract, islets of the pancreas, lung, adrenal medulla, thyroid C-cells, etc., and are heterogeneous groups of neoplasms with unique tumor biology, natural history, and clinical management issues. Most NETs are sporadic, but they can be part of familial cancer syndromes such as multiple endocrine neoplasia type 1 (MEN1), multiple endocrine neoplasia type 2A/B neurofibromatosis type 1 (NF1) or Von Hippel–Lindau (VHL) syndrome. The standard treatment for localized NETs is surgical resection; however, a variety of therapeutic options are available for patients with advanced NETs. When to apply a given option, what combination therapeutic approach should be used, how long treatment should be continued remain unclear and controversial topics. Moreover, patients with these endocrine cancers seek expert advice in the management of their care. This Special Issue will is a collaboration of research which will help us to further understand the biology of endocrine cancers.

*cancers*

IMPACT FACTOR 4.5 | Indexed in: PubMed | CITESCORE 8.0

an Open Access Journal by MDPI

## Editor-in-Chief

**Prof. Dr. Samuel C. Mok**
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.
**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.
**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

*Cancers* Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
𝕏@Cancers_MDPI